New Delhi: Aurobindo Pharma has received a major blow from the US FDA, the US drug regulator. The USFDA has canceled the VAI letter, which was given to Unit Four of the company, a clean chit. The company has reported that a US-FDA investigation is currently underway. Significantly, on Wednesday, Auro Pharma’s stock gained more than 20% due to the news of clean chit.
Let us know that the US-FDA has canceled the clean chit given to Aurobindo Pharma’s Unit IV plant. The US-FDA investigation, which has been underway since November 19, has not yet closed. The US-FDA has provided this information on its website. Aurobindo Pharma gained 20% on Wednesday from the news of a clean chit. Emkay says the withdrawal of clean chit would be extremely negative for the stock.
